After a comprehensive consideration combining the druggability evaluation of small molecules and the stability of binding conformation, aminopterin emerged as the prior candidate and demonstrated significant STK3-inhibiting and tumor-suppressing effects in vitro. The gene discussed is STK3; the disease is neoplasm.